- Home
- XFOR vs LUCD Comparison
XFOR vs LUCD Comparison
Compare XFOR & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- LUCD
- Stock Information
- Founded
- XFOR 2014
- LUCD 2018
- Country
- XFOR United States
- LUCD United States
- Employees
- XFOR N/A
- LUCD N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- XFOR Health Care
- LUCD Health Care
- Exchange
- XFOR Nasdaq
- LUCD Nasdaq
- Market Cap
- XFOR 118.4M
- LUCD 135.6M
- IPO Year
- XFOR N/A
- LUCD 2021
- Fundamental
- Price
- XFOR $3.40
- LUCD $1.40
- Analyst Decision
- XFOR Strong Buy
- LUCD Strong Buy
- Analyst Count
- XFOR 3
- LUCD 4
- Target Price
- XFOR $72.33
- LUCD $3.88
- AVG Volume (30 Days)
- XFOR 180.2K
- LUCD 1.1M
- Earning Date
- XFOR 05-01-2025
- LUCD 05-14-2025
- Dividend Yield
- XFOR N/A
- LUCD N/A
- EPS Growth
- XFOR N/A
- LUCD N/A
- EPS
- XFOR 2.16
- LUCD N/A
- Revenue
- XFOR $31,364,000.00
- LUCD $4,173,000.00
- Revenue This Year
- XFOR $915.88
- LUCD $98.50
- Revenue Next Year
- XFOR N/A
- LUCD $208.02
- P/E Ratio
- XFOR $1.57
- LUCD N/A
- Revenue Growth
- XFOR N/A
- LUCD 39.89
- 52 Week Low
- XFOR $2.67
- LUCD $0.68
- 52 Week High
- XFOR $33.90
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- XFOR 39.83
- LUCD 58.18
- Support Level
- XFOR $2.67
- LUCD $1.21
- Resistance Level
- XFOR $3.56
- LUCD $1.70
- Average True Range (ATR)
- XFOR 0.28
- LUCD 0.11
- MACD
- XFOR 0.21
- LUCD 0.03
- Stochastic Oscillator
- XFOR 82.02
- LUCD 60.48
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.